NicVAX
NicVAX is a vaccine that was developed by Nabi Biopharmaceuticals to help in the treatment of nicotine addiction. It works by stimulating the immune system to produce antibodies that bind to nicotine, preventing it from reaching the brain and thereby reducing the pleasurable effects of smoking and helping individuals to quit.
History[edit | edit source]
NicVAX was developed by Nabi Biopharmaceuticals, a company that specializes in the development of vaccines for infectious diseases and other disorders. The vaccine was first announced in 2005, and it entered Phase III clinical trials in 2007. However, in 2011, the company announced that the vaccine had failed to meet its primary endpoint in these trials, and development was subsequently discontinued.
Mechanism of action[edit | edit source]
The active ingredient in NicVAX is a hapten called 3'-aminomethylnicotine, which is chemically similar to nicotine. When this hapten is injected into the body, it stimulates the immune system to produce antibodies that recognize and bind to nicotine. Once these antibodies are present in the bloodstream, they can bind to nicotine molecules that enter the body when a person smokes a cigarette. This prevents the nicotine from reaching the brain, where it would normally bind to nicotinic acetylcholine receptors and trigger the release of dopamine, a neurotransmitter that is associated with feelings of pleasure and reward. By blocking the effects of nicotine in this way, NicVAX helps to reduce the desire to smoke and makes it easier for individuals to quit.
Clinical trials[edit | edit source]
NicVAX underwent a series of clinical trials to assess its safety and efficacy. The Phase I and II trials, which were conducted between 2005 and 2007, showed that the vaccine was safe and well-tolerated, and that it could stimulate the production of anti-nicotine antibodies. However, the Phase III trials, which were conducted between 2007 and 2011, failed to show a significant difference in quit rates between individuals who received the vaccine and those who received a placebo. As a result, development of the vaccine was discontinued.
See also[edit | edit source]
References[edit | edit source]
| NicVAX Resources | |
|---|---|
|
 |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
